These case reports look at two patients with anti-N-methyl-D-aspartate receptor (NMDAr) encephalitis presenting to  the same acute medical unit within a month of each other. The following covers the characteristic signs, symptoms and timeline associated with this condition and discusses whether we should be sending CSF for anti-NMDAr antibody testing more readily.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methylD-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61(1): 25–36.
2. Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology.2017; 88(4): 366–370.
3. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2): 157–165.
4. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014; 13(2):167–177.
5. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7(12): 1091–1098.
6. Barry H, Byrne S, Barrett E, et al. Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull. 2015; 39(1): 19–23.
7. Gable M, Sheriff H, Dalmau J, et al. The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. Clinical Infectious Diseases. 2012; 54(7): 899–904.
8. Granerod J, Ambrose HE, Davies NWS, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-base prospective study. Lancet Infectious Diseases. 2010; 10(12): 835–844.
9. Varley JA, Webb AJS, Balint B, et al. The Movement disorder Associated with NMDAR Antibody Encephalitis Is Complex and Characteristic: An Expert Video-Rating study. Journal Neurology, Neurosurgery and Psychiatry. 2019; 90(6): 724–726.
10. Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2019; 7(1): 93–108.
11. Westman G, Studahl M, Ahlm C, et al. N-methyl-d-asparatate Receptor Autoimmunity Affects Cognitive Performance in Herpes Simplex Encephalitis. Clinical Microbiology and Infection.2016; 22(11): 934–940.
12. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with antiNMDAR encephalitis. Lancet Neurol. 2011; 10(1): 63–74.
13. Huang C, Kang Y, Zhang B, et al. Anti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatment. Neuropsychiatr Dis Treat. 2015; 11: 1437–1442.
14. Lebon S, Mayor-Dubois C, Popea I, et al. Anti-N-methyl-Daspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent. J Child Neurol. 2012; 27(12):1607–10.
15. Xia R, Zhenzhen X, Bingrong C, et al. Case report of anti-Nmethyl-D-aspartate receptor encephalitis in a middle-aged woman with a long history of major depressive disorder. BMC Psychiatry.2017; 17: 320.
16. Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults: Association of British Neurologists and British Infection Association National Guideline. Journal of Infection. 2012; 64(4): 347–373.